GlassScriptPhysician profile
Sarju Waghela
NPI 1033377692
$1,099.26
in general payments reported to CMS, 2019-2025
23 companies · $564 in 2025
The $564 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $10.98 · 2021: $189 · 2022: $139 · 2023: $90.33 · 2024: $105 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.23 |
| Education | $116.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $133.49 | 2022-2025 | Reblozyl |
| Astellas Pharma US INC | $130.31 | 2025 | Xtandi |
| Lilly USA, LLC | $111.49 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Epizyme, INC. | $99.95 | 2021 | |
| Pharmaessentia USA Corporation | $94.73 | 2025 | Besremi |
| Array Biopharma INC | $73.08 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Novartis Pharmaceuticals Corporation | $54.44 | 2023-2025 | |
| Incyte Corporation | $48.87 | 2021-2022 | |
| Abbvie INC. | $47.77 | 2025 | |
| Kite Pharma, INC. | $45.37 | 2023-2025 | Yescarta |
| Gilead Sciences, INC. | $38.22 | 2021-2025 | Trodelvy |
| Acrotech Biopharma INC. | $35.91 | 2021-2022 | |
| Sirtex Medical INC | $26.67 | 2023 | Sir-Spheres Microspheres |
| Merck Sharp & Dohme LLC | $23.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.33 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2025 | Fruzaqla |
| Amgen INC. | $15.99 | 2023 | Xgeva, Nplate, Vectibix |
| Genzyme Corporation | $15.77 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.54 | 2021 | |
| Seagen INC. | $13.29 | 2022 | |
| Glaxosmithkline, LLC. | $12.40 | 2022 | |
| Janssen Biotech, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarju Waghela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.